From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

Tissue Regenix – is it really “strong H1 results” & “a strong cash position” from this former Neil Woodford dog?

By Steve Moore | Wednesday 8 September 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Tissue Regenix (TRX) has announced results for the first half of 2021 claiming “we have created a commercially focussed regenerative global medtech company in a high growth sector… encouraged by our strong H1 results” and that we “look forward to this being further built on in H2”. So why are the shares, at 0.675p, currently more than 4% lower?

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



That Was the Week that Was

 

ICON

Iconic Labs – its alive!

Wednesday »

Bearcast

Tom Winnifrith Bearcast: Family tales

 

SHG

Shanta Gold – a recovery BUY!

 

MUSH

Oscillate RTO – madness

 

MOON

Surely Moonpig is a short at 171p?

 

Atomic

Video: The Road to an Energy Crisis

 

Bear

Beyond Meat is Beyond Redemption.

Friday »

Bearcast

Tom Winnifrith bearcast: Madness!

 

RRR

The Andrew Bell defence at Red Rock

 

ARB

Kicking two men who are down